§ 812.46. Monitoring investigations.
234 words·~1 min read·
/us/cfr/t21/s§ 812.46·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
(a)Securing compliance. A sponsor who discovers that an investigator is not complying with the signed agreement, the investigational plan, the requirements of this part or other applicable FDA regulations, or any conditions of approval imposed by the reviewing IRB or FDA shall promptly either secure compliance, or discontinue shipments of the device to the investigator and terminate the investigator's participation in the investigation. A sponsor shall also require such an investigator to dispose of or return the device, unless this action would jeopardize the rights, safety, or welfare of a subject.
(b)Unanticipated adverse device effects.
(1)A sponsor shall immediately conduct an evaluation of any unanticipated adverse device effect.
(2)A sponsor who determines that an unanticipated adverse device effect presents an unreasonable risk to subjects shall terminate all investigations or parts of investigations presenting that risk as soon as possible. Termination shall occur not later than 5 working days after the sponsor makes this determination and not later than 15 working days after the sponsor first received notice of the effect.
(c)Resumption of terminated studies. If the device is a significant risk device, a sponsor may not resume a terminated investigation without IRB and FDA approval. If the device is not a significant risk device, a sponsor may not resume a terminated investigation without IRB approval and, if the investigation was terminated under paragraph (b)(2) of this section, FDA approval.
Connections1 cite this
Cited by 1 section
register
Citation graph
cites case law
§ 812.46
Monitoring investigations.
Fed. Reg.×1
Cites 0Cited by 1 across 1 source